Recombinant Human Calnexin (CANX) is a laboratory-engineered form of the endoplasmic reticulum (ER) chaperone protein, designed for studying protein folding, quality control mechanisms, and ER-associated degradation pathways . Produced in heterologous expression systems like Escherichia coli or HEK293 cells, it retains functional properties of native calnexin, including calcium-binding and glycoprotein interaction capabilities .
Recombinant CANX is synthesized using advanced expression systems:
Expression Hosts:
Purification: Anti-DDK affinity chromatography followed by ion-exchange or size-exclusion chromatography .
Retains misfolded glycoproteins in the ER via interaction with monoglucosylated oligosaccharides .
Collaborates with ERp57 to catalyze disulfide bond formation in MHC class I molecules .
Charcot-Marie-Tooth Disease: Mutant PMP22 proteins sequestered by calnexin fail to traffic to Schwann cells, impairing myelination .
Multiple Sclerosis (MS): Calnexin regulates T cell transmigration across the blood-brain barrier, as shown in experimental autoimmune encephalomyelitis (EAE) models .
SARS-CoV-2: Calnexin/calreticulin chaperones facilitate Spike protein maturation; knockout cells show reduced viral entry .
Calnexin levels decline with age, correlating with increased susceptibility to ER stress-related pathologies .
SARS-CoV-2: CANX/CALR knockout 293T cells exhibit reduced Spike protein incorporation into pseudoviruses, highlighting its role in viral assembly .
Mice with T cell-specific Canx deletion develop EAE normally, suggesting calnexin’s role is endothelial-specific .
Emerging studies focus on: